ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Induction therapy"

  • 2018 American Transplant Congress

    The BEST Trial: A Prospective Randomized Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression

    E. Woodle,1 D. Kaufman,2 A. Shields,1 J. Leone,3 A. Wiseman,4 A. Matas,5 P. West-Thielke,6 E. King,1 R. Alloway.1

    1U Cincinnati, Cincinnati; 2U Wisconsin, Madison; 3Tampa General, Tampa; 4U Colorado, Denver; 5U Minnesota, Minneapolis; 6UIC, Chicago.

    Previous large multicenter belatacept (BELA)-based CNI- and steroid-free immunosuppressive trials have not enrolled to completion due to safety concerns. The BEST Trial (Belatacept-based Early Steroid…
  • 2018 American Transplant Congress

    B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression

    Q. Gao,1 A. Mehta,2 A. Guasch,2 A. Ghali,2 A. Kirk,1 H. Xu.1

    1Department of Surgery, Duke University Medical Center, Durham, NC; 2Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.

    Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…
  • 2018 American Transplant Congress

    A Comparison of Alemtuzumab versus Antithymocyte Globulin Induction in High-Risk, Non-Sensitized Renal Transplant Recipients

    S. Patel, A. Lichvar, E. Benedetti, P. West-Thielke.

    University of Illinois Hospital and Health Sciences System, Chicago.

    Background: Lymphocyte depleting induction is routinely utilized in high immunologic risk renal transplant (RTx). African Americans (AA) have a relatively higher risk of rejection regardless…
  • 2018 American Transplant Congress

    Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Heart/Kidney Transplantation

    I. Moinuddin, J. Yu, L. Kang, C. Bhati, D. Bandyopadhyay, A. King, D. Kumar, L. Kamal, D. Tang, I. Yakubu, G. Gupta.

    Virginia Commonwealth University, Richmond.

    Introduction: There is no published data on the risks and benefits of Induction immunosuppression in simultaneous heart/kidney transplant (SHKT) patients.Methods: We analyzed all SHKT performed…
  • 2018 American Transplant Congress

    Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction

    Q. Gao,1 A. Mehta,2 A. Guasch,2 L. Stempora,1 A. Kirk,1 H. Xu.1

    1Department of Surgery, Duke University Medical Center, Durham, NC; 2Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.

    Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…
  • 2018 American Transplant Congress

    The Influence of Rabbit Antithymocyte Globulin (rATG) Dose on the Incidence of CMV Infection in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis. A Propensity Score Matched Cohort Analysis

    M. Ivani de Paula,1,2 S. Bae,1 J. Garonzik-Wang,1 C. Felipe,2 M. Cristelli,2 A. Massie,1,3 J. Medina-Pestana,2 D. Segev,1,3 H. Tedesco Silva J�nior.2

    1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; 2Department of Nephrology, Hospital do Rim, Universidade Federal de Sao Paulo, Sao Paulo, Brazil; 3Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, Brazil.

    rATG has become the agent of choice for induction therapy in sensitized patients and those receiving expanded criteria donors (ECD) allografts. However, the optimal dose…
  • 2017 American Transplant Congress

    Impact of T-Cell Depletion on CMV-Specific Memory T and B Cell Homeostatic Proliferation After Kidney Transplantation.

    M. Jarque,2 S. Luque,2 E. Crespo,2 E. Melilli,1 J. Torras,1,2 J. Grinyó,1,2 O. Bestard.1,2

    1Kidney Transplant Unit, Bellvitge University Hospital, Barcelona, Spain; 2Nephrology Laboratory, IDIBELL, Barcelona, Spain

    Human CMV infection is the most common opportunistic infection after kidney transplantation, with a negative impact on kidney allograft outcome. Transplant recipients are at higher…
  • 2017 American Transplant Congress

    Alemtuzumab Induction Is Safe, and Permits the Avoidance of Steroids in the Majority of Renal Transplant Recipients.

    A. Seitz,1 M. Robb,2 N. Ahmad,1 A. McLean,3 D. Taube,3 R. Johnson,2 R. Baker.1

    1Renal Unit, St James's Hospital, Leeds, United Kingdom; 2Organ Donation and Transplantation Studies, NHS Blood and Transplant, Bristol, United Kingdom; 3West London Renal and Transplant, Hammersmith Hospital, London, United Kingdom

    IntroductionThe introduction of alemtuzumab into routine clinical use has been hindered by safety concerns surrounding its prolonged effect on the lymphoid compartment. Here we report…
  • 2017 American Transplant Congress

    Benefits of Induction in Recipients of Acute Renal Failure Donor Kidneys.

    M. Barrett, A. Smith, K. Woodside, R. Sung.

    University of Michigan, Ann Arbor

    Kidneys from donors with acute renal failure (ARF) are often discarded due to concerns for DGF and graft failure. Induction immunosuppression can be used to…
  • 2017 American Transplant Congress

    National Variation in US Kidney Transplant Induction Therapy.

    V. Dharnidharka,1 A. Naik,2 T. Alhamad,1 D. Axelrod,3 M. Schnitzler,4,6 Z. Zhang,4 S. Bae,5 D. Brennan,1 D. Segev,5 H. Randall,4 M. Nazzal,4 R. Ouseph,4 B. Kasiske,6 K. Lentine.4

    1Washington Univ, St. Louis, MO; 2U Michigan, Ann Arbor, MI; 3East Carolina Univ, Greenville, NC; 4St. Louis Univ, St. Louis, MO; 5Johns Hopkins, Baltimore, MD; 6Scientific Registry of Transplant Recipients, Minneapolis, MN

    Antibody induction (IND) therapy in kidney transplantation (KTx) reduces acute rejection risk but adds to transplant cost. Currently, only IL2 Receptor antibodies (IL2R-Ab) have FDA…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 31
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences